ArticleWorld journal of gastrointestinal oncology2025
Oxocrebanine inhibits the proliferation of hepatocellular carcinoma cells by promoting apoptosis and autophagy.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFinding active lead anti-hepatocellular carcinoma compounds from traditional Chinese medicine has important research value.
aimTo assess the detailed mechanism of oxocrebanine, a compound separated from the traditional Chinese medicinal plant
methodsMTT, BrdU labeling, and colony formation assays were used to assess the inhibitory effect of oxocrebanine on the growth and proliferation of human hepatocellular carcinoma Hep3B2.1-7 cells. Flow cytometry was used to detect the effect of oxocrebanine on the apoptosis of Hep3B2.1-7 cells. Western blotting was used to assess the expression of apoptosis-related proteins in Hep3B2.1-7 cells. The aforementioned methods were also used to evaluate the effects of oxocrebanine on cell proliferation, autophagy markers, and autophagy-related protein expression levels after adding autophagy inhibitor 3-mA. Furthermore, to verify the anti-hepatocellular carcinoma effect of oxocrebanine
resultsOxocrebanine effectively inhibited the growth of Hep3B2.1-7 cells, whilst upregulating the protein expression of cleaved caspase-3, downregulating poly(ADP-ribose) polymerase 1 protein expression, increasing the levels of Bax and Bcl-2 antagonist/killer 1 protein expression, and decreasing the levels of Bcl-2 and myeloid cell leukemia 1 protein expression, which could promote apoptosis in Hep3B2.1-7 cells. Oxocrebanine promoted the transformation of LC3-I to LC3-II in Hep3B2.1-7 cells, suggesting the occurrence of autophagy, whilst the autophagy inhibitor 3-MA could reverse this process. Oxocrebanine was also shown to reduce the phosphorylation levels of the eukaryotic translation initiation factor 4EBP1 and ribosomal protein S6 kinase B1 (P70S6K), two downstream effector molecules in the PI3K/Akt/mTOR pathway, inducing autophagy in Hep3B2.1-7 cells. Moreover, the tumor-bearing nude mouse experiment indicated that oxocrebanine effectively inhibited the growth of Hep3B2.1-7 cells
conclusionOxocrebanine can inhibit the proliferation of human hepatocellular carcinoma cells by promoting apoptosis and inducing autophagy
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.